Exelixis' XL092 To Be Tested In Combination With Bavencio In Urothelial Carcinoma


Exelixis Inc EXEL has announced a clinical trial collaboration and supply agreement with Germany's Merck KGaA and Pfizer Inc PFE for the ongoing Phase 1b dose-escalation study STELLAR-001.

  • The study will add three new cohorts that will evaluate the safety and tolerability of Exelixis' XL092, in combination with Merck/Pfizer's Bavencio (avelumab), in patients with locally advanced or metastatic urothelial carcinoma (UC).
  • Exelixis is sponsoring the STELLAR-001 trial, and Merck KGaA and Pfizer will provide avelumab for use in the trial.
  • Additional expansion cohorts include maintenance therapy, patients who have progressed following treatment with an immune checkpoint inhibitor, and patients previously treated with platinum-containing chemotherapy.
  • XL092 is an investigational, next-generation oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in the growth and spread of cancer.
  • Price Action: EXEL shares are trading 0.86% higher at $23.35 in premarket trading on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsFDAGeneralUrothelial Cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!